Advertisement

The Chemotherapy of Bladder Carcinoma: Systemic Therapy

  • W. G. Harker
  • F. M. Torti
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 85)

Abstract

While chemotherapy advances in other genitourinary malignancies (e.g., Wilm’s tumor and testicular carcinoma) have led to improved disease-free survival and presumed cure, drug therapy of bladder carcinoma remains in a developmental stage. Carcinoma of the urinary bladder ranks seventh in males and 13th in females among causes of death in the United States due to cancer. Approximately 30,000 new cases are reported annually in the U.S. with approximately 10,000 deaths per year attributed to bladder carcinoma [56]. The incidence in males is threefold that in females. Over 60% of these patients are between the ages of 50 and 70 years old [15]. Surgery and radiation are curative modalities. Preoperative staging of the extent of tumor infiltration of the bladder wall is highly predictive of complete resectability and thus probability of cure. While combined modality therapy with preoperative radiotherapy and radical cystectomy has been shown to reduce the loco-regional recurrence rate, there is little evidence that therapy alters the subsequent development of distant metastases [72], It is not surprising then that the 5-year survival of patients with invasive bladder carcinoma treated with the most expert radiation therapy and surgery, alone or in combination, is between 20% and 50% [16]. Systemic chemotherapy is the only treatment modality with the potential for cure in patients presenting with locally unresectable disease or who develop local or disseminated metastatic involvement after presumed curative initial therapy.

Keywords

Bladder Cancer Radical Cystectomy Transitional Cell Carcinoma Bladder Carcinoma Proc ASCO 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Altman CC, McCague NJ, Ripepi AC, Cardoza M (1972) The use of methotrexate in advanced carcinoma of the bladder. J Urol 198:217–273Google Scholar
  2. 2.
    Altman S: Yoshi 864 (1978) 1 propanol, 3,3’-Iminodi-dimethane sulfonate (ester) hydrochloride: A phase II study in solid tumors. Cancer Treat Rep 62:389–395PubMedGoogle Scholar
  3. 3.
    Al-Sarraf M, Amer MH, Vaitkevicius VK (1977) Chemotherapy and survival in patients with urinary bladder cancer. Proc AACR and ASCO 18:146Google Scholar
  4. 4.
    Andrews MC, Wilson WL (1976) Phase II study of methotrexate (NSC-740) in solid tumors. Cancer Chemother Rep 51:471–474Google Scholar
  5. 5.
    Blum RH, Livingston RB, Carter SK (1973) Hexamethylmelamine — a new drug with activity in solid tumors. Eur J Cancer 9:195–202PubMedGoogle Scholar
  6. 6.
    Blumenreich M, Yagoda A, Watson RC, Needles B (1981) Phase II trial of vinblastine sulfate (VLB) in transitional cell carcinoma. Proc ASCO 22:466Google Scholar
  7. 7.
    Bonadonna G, Monfardini S, DeLena M, Fossati-Bellani F, Beretta G (1972) Clinical Trials with Adriamycin — results of three year study. In: Carter SK, DiMarco A, Ghione M (eds) International symposium on adriamycin. Springer, New York, 139–152Google Scholar
  8. 8.
    Burfield GD (1972) Intravenous methotrexate in the treatment of advanced bladder cancer. Br J Urol 44:121–124PubMedGoogle Scholar
  9. 9.
    Campbell M, Baker LH, Opipaui M, Al-Sarraf M (1981) Phase II trial with cisplatin, doxorubicin, cyclophosphamide (CAP) in the treatment of urothelial cell carcinoma. Cancer Treat Rep 65:897–899PubMedGoogle Scholar
  10. 10.
    Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36:729–747PubMedCrossRefGoogle Scholar
  11. 11.
    Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Adriamycin given as a weekly schedule without a loading course: clinical effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47–51PubMedGoogle Scholar
  12. 12.
    Collier D, Soloway MS (1976) Doxorubicin hydrochloride, cyclophosphamide, a 5-fluoro- uracil combination in advanced prostate and transitional cell carcinoma. Urology 8:459–464PubMedCrossRefGoogle Scholar
  13. 13.
    Corder MP, Cicmil GA (1976) Effective treatment of metastatic squamous cell carcinoma of the prostate with adriamycin. J Urol 155:222Google Scholar
  14. 14.
    Cross RJ, Glashan RW, Humphrey CS, Robinson MRG, Smith PH, Williams RE (1976) Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. Br J Urol 48:609–615PubMedCrossRefGoogle Scholar
  15. 15.
    Dean AL, Mostofi FK, Thomson RU, Clark RL (1954) A restudy of the first 1400 tumors in the bladder tumor registry, AFIP. J Urol 71:571–590PubMedGoogle Scholar
  16. 16.
    de Kernion JB (1977) The chemotherapy of advanced bladder carcinoma. Cancer Res 37:2771–2774Google Scholar
  17. 17.
    Early K, Elias EG, Mittelson A, Albert D, Murph GP (1973) Mitomycin C in the treatment of metastatic transitional cell carcinoma of the bladder. Cancer 31:1150–1153PubMedCrossRefGoogle Scholar
  18. 18.
    Einstein A, Soloman M, Corder M, Bonney W, Coombs J (1981) Diamine dichloropla- tinum (DDP) vs DDP plus cyclophosphamide (CY) for metastatic bladder carcinoma. A National Bladder Cancer Collaborative Group A (NBCCGA) study. Proc ASCO 22:461Google Scholar
  19. 19.
    EORTC (1977) The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-FU. Eur Urol 3:276–278Google Scholar
  20. 20.
    Fox M (1965) The effect of cyclophosphamide on some urinary tract tumors. Br J Urol 37:399–403PubMedCrossRefGoogle Scholar
  21. 21.
    Gad-El-Mawla NM, Ziegler JL (1978) Phase II trial of bleomycin in bilharzal bladder cancer. Cancer Treat Rep 62:1109–1110PubMedGoogle Scholar
  22. 22.
    Gagliano R (1980) Adriamycin versus adriamycin plus cisplatin in transitional cell bladder carcinoma. A SWOG study. Proc ASCO 21:347Google Scholar
  23. 23.
    Glenn J, Hunt L, Cathem J (1963) Chemotherapy of bladder cancer with 5-Fluorouracil. Cancer Chemother Rep 27:67–69PubMedGoogle Scholar
  24. 24.
    Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Jr, Bordin LA, Braun TJ, Young CW (1982) Antiemetic efficacy of high-dose metoclophramide: randomized trails with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909CrossRefGoogle Scholar
  25. 25.
    Hall RR, Bloom HJG, Freeman JE, Nawrocki A, Wallace DM (1971) Methotrexate treatment for advanced bladder cancer. Br J Urol 46:431–438CrossRefGoogle Scholar
  26. 26.
    Herr HW (1980) Cis-diamminedichloride platinum (II) in the treatment of advanced bladder cancer. J Urol 853–855Google Scholar
  27. 27.
    Holland JF, Scharlan C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BF, Lynch JJ, Owens A, Carbone PP, Colby J, Grob D, Miller SP, Hall TC (1973) Vincristine treatment of advanced cancer. A cooperative study of 392 cases. Cancer Res 33:1258–1264PubMedGoogle Scholar
  28. 28.
    Ikic D, Maricic Z, Oresic V, Rode B, Nola P, Smudj K, Knezevic M, Jusic D (1981) Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet 1:1022–1024PubMedGoogle Scholar
  29. 29.
    Jacobs C, Bertino JR, Goffinet DR, Fee WR, Goode RL (1978) 24-hour infusion of cisplatinum in head and neck cancers. Cancer 42:2135–2140Google Scholar
  30. 30.
    Kedia KR, Gibbons C, Persky L (1981) The management of advanced bladder carcinoma. J Urol 125:655–658PubMedGoogle Scholar
  31. 31.
    Khandekar JD, Elson PJ, DeWys WD, Slayton R (1981) Comparative activity and toxicity of cis-diammine-dichloroplatinum (DDP) vs cyclophosphamide (CTX) Adriamycin (ADR) and DDP (CAD) in disseminated transitional cell carcinomas of the urinary tract (DTCUT). Proc ASCO 22:461Google Scholar
  32. 32.
    Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reductin of doxorubicin cardiotoxicity by prolonged continous intravenous infusion. Ann Intern Med 46:133–139Google Scholar
  33. 33.
    Macdonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunei R, Lagarde C (1980) 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Int Med 43:533–536Google Scholar
  34. 34.
    Martino S, Samal B, Al-Sarraf M (1980) Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract. Cancer Treat Rep 64:161–163PubMedGoogle Scholar
  35. 35.
    Mechl Z, Rovny F, Sopkova B (1977) VM-26 (4 demethyl-epipodo phyllotoxin-B-d- theonylidine glucoside) in the treatment of urinary bladder tumors. Neoplasma 24 (4): 411PubMedGoogle Scholar
  36. 36.
    Merrin C (1975) Treatment of advanced bladder cancer with cisdiammine dichloroplatinum (II) (NSC 119875): a pilot study. J Urol 114:884–887PubMedGoogle Scholar
  37. 37.
    Merrin C, Cartegena R, Wajsman Z, Baumgardner C, Murphy GP (1975) Chemotherapy of bladder cancer with Cytoxan and adriamycin. J Urol 114:884–887PubMedGoogle Scholar
  38. 38.
    Middleman E, Luce J, Frei E (1971) Clinical trials with adriamycin. Cancer 28:844–850PubMedCrossRefGoogle Scholar
  39. 39.
    Mills RC, Maurer LH, Forcier RJ, Grace WR, Burke GP, Karp DO, Smith RL, Mclntyre OR, Bean C (1977) Clinical trial of combined therapy with adriamycin and cisdichlor- odiammineplatinum (II). Cancer Treat Rep 61:477–479PubMedGoogle Scholar
  40. 40.
    Moore G, Bross ID, Ausman R, Nadler S, Jones R, Slack N, Reimm A (1963) Effects of 5-fluorouracil (NSC 19893) in 389 patients with cancer. Cancer Chemother Rep 27: 67–69Google Scholar
  41. 41.
    Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Brain DW, Jr (1981) Methotrexate: an active drug in bladder cancer. Cancer 47:1246–1250PubMedCrossRefGoogle Scholar
  42. 42.
    Natale RB, Yagoda A, Watson RC, Stover DE (1980) Phase II trial of neocarzinostatin in patients with bladder and prostate cancer: toxicity of a five day I.V. bolus schedule. Cancer 45:2836–2842PubMedCrossRefGoogle Scholar
  43. 43.
    O’Bryan RM, Luce JK, Talley TW, Gottlieb JA, Baker LH, Bonadonna G (1973) Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1–8PubMedCrossRefGoogle Scholar
  44. 44.
    Omura J, Okita K, Tasaka S (1962) Chemotherapy of cancer of the urinary bladder. Bull Cancer Inst Okayama Univ 2:143–156Google Scholar
  45. 45.
    Panduro J, Hansen M, Hansen HH (1981) Oral VP-16–213 in transitional cell carcinoma of the bladder: A Phase II study. Cancer Treat Rep 65:703–704PubMedGoogle Scholar
  46. 46.
    Pannuti F, Martoni A, Casadio M, Fruet F, Belfiore G (1979) New regimen of combination chemotherapy (CHW) in the treatment of advanced bladder cancer: a pilot study. Cancer Treat Rep 63:1427–1428PubMedGoogle Scholar
  47. 47.
    Pavone-Macaluso M (1971) Chemotherapy of vesical and prostatic tumors. Br J Urol 43:701–708PubMedCrossRefGoogle Scholar
  48. 48.
    Pavone-Macaluso M (1976) EORTC genitourinary tract cooperative group: a single-day chemotherapy of bladder cancer with adriamycin, VM-26, or bleomycin. Eur Urol 2:138Google Scholar
  49. 49.
    Price LA, Goldie JH (1971) Multiple drug therapy for disseminated malignant tumors. Br Med J 4: 336–339PubMedCrossRefGoogle Scholar
  50. 50.
    Prout GR, Bross IDJ, Slack NH, Ausman RK (1968) Carcinoma of the bladder, 5-fluorouracil and the critical role of a placebo: a cooperative group report. I. Cancer 22:926–931Google Scholar
  51. 51.
    Rodriguez LH, Johnson DE, Holoye PY, Samuels MC (1977) Combination VM-26 and adriamycin for metastatic transitional cell carcinoma. Cancer Treat Rep 61: 87–88PubMedGoogle Scholar
  52. 52.
    Rossof AH, Talley RW, Stephens RL (1977) Phase II evaluation of single high dose cisdiammine dichloroplatinum (II) (NCS-119875, CACP) in gynecologic (GYN) and genitourinary (GU) neoplasia. Proc ASCR and ASCO 18:99Google Scholar
  53. 53.
    Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C, Eyre HJ, Fisher R (1979) Phase II evaluation of cis dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Cancer Treat Rep 63:1557–1564PubMedGoogle Scholar
  54. 54.
    Sakamoto S, Ogata J, Ikegami K, Naeda H (1978) Effects of systemic administration of neocarsinostatin, a new protein antibiotic on human bladder cancer. Cancer Treat Rep 62:453–454PubMedGoogle Scholar
  55. 55.
    Samuels ML, Logothetis C, Trindade A, Johnson PE (1980) Cytoxan, adriamycin and cisplatinum (CISCA) in metastatic bladder cancer. Proc AACR 21:137Google Scholar
  56. 56.
    Silverberg E (1978) Cancer Statistics, CA 28:17–30PubMedCrossRefGoogle Scholar
  57. 57.
    Swalley RV, Bartolucci AA, Hemstret G, Hester M (1981) A phase II evaluation of a 3 drug combination of cyclophosphamide, doxorubicin, and 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostate cancer. J Urol 125:191–195Google Scholar
  58. 58.
    Soloway MS (1978) Cis diammine dichloroplatinum (II)(DDP) in advanced bladder cancer. Proc ASCO 19:366Google Scholar
  59. 59.
    Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37:2918–2929PubMedGoogle Scholar
  60. 60.
    Soloway MS, Jicard M, Ford K (1981) Cis-diamminedichloroplatinum (II) in locally advanced and metastatic cancer. Cancer 47:476–480PubMedCrossRefGoogle Scholar
  61. 61.
    Sternberg JJ, Bracken RB, Handel PB, Johnson DE (1977) Combination chemotherapy (CISCA) for advanced urinary tract carcinoma: a preliminary report. JAMA 238:2282–2287PubMedCrossRefGoogle Scholar
  62. 62.
    Sullivan RD (1962) Intra-arterial methotrexate therapy: The dose, duration and route of administration studies of methotrexate in clinical cancer chemotherapy. In: Porter R, Wiltshaw E (eds) First symposium on methotrexate in the treatment of cancer. Wright Bristol 50–55Google Scholar
  63. 63.
    Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J, Murphy ML, Krakoff IH (1973) Adriamycin — an antitumor antibiotic in treatment of neoplastic disease. Cancer 32:9–17PubMedCrossRefGoogle Scholar
  64. 64.
    Tannock I, Gospodarowicz M, Evans WK (1981) Methotrexate, adriamycin and cyclophosphamide (MAC) chemotheraphy for transitional cell carcinoma of the urinary tract. Proc ASCO 461Google Scholar
  65. 65.
    Troner M, Hemstreet G (1978) Cyclophosphamide, adriamycin and cisplatin (CAP) chemotherapy of metastatic transitional cell carcinoma of the bladder. Proc AACR 19:161Google Scholar
  66. 66.
    Turner AG, Hendry WF, Williams GB, Bloom HJG (1977) The treatment of advanced bladder carcinoma with methotrexate. Br J Urol 49: 673–678PubMedCrossRefGoogle Scholar
  67. 67.
    Vogl S, Ohnuma T, Perloff M, Holland JF (1976) Combination chemotherapy with adriamycin and cis-diamminedichloroplatinum in patients with metastatic diseases. Cancer 38:21–26PubMedCrossRefGoogle Scholar
  68. 68.
    Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717Google Scholar
  69. 69.
    Weinstein S, Schmidt J (1976) Doxorubicin chemotherapy in advanced transitional cell carcinoma. Urology 8:336–341PubMedCrossRefGoogle Scholar
  70. 70.
    Weiss A, Jackson L, Carabasi R (1961) An evaluation of 5-fluorouracil in malignant disease. Ann Intern Med 55:731–741PubMedGoogle Scholar
  71. 71.
    Weiss AJ, Manthel RW (1977) Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 40:2046–2052PubMedCrossRefGoogle Scholar
  72. 72.
    Whitmore WF Jr, Batata MA, Ghoneim MA, Grabstald H, Unal A, (1977) Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 118:184–187PubMedGoogle Scholar
  73. 73.
    Williams SD, Einhorn LH, Donohue JP (1979) Cisplatin Combination chemotherapy of bladder cancer. Cancer Clin Trials 2:335–338PubMedGoogle Scholar
  74. 74.
    Williams SD, Röhn RI, Donohue JP, Einhorn LH (1978) Chemotherapy of bladder cancer with cis-diamminedichloroplatinum (DDP), adriamycin (ADR), and 5-fluorouracil (5-FU). Proc ASCO 19:316Google Scholar
  75. 75.
    Wilson WL (1960) Chemotherapy of human solid tumors with 5-fluorouracil. Cancer 13:1230–1239PubMedCrossRefGoogle Scholar
  76. 76.
    Wilson WL, Schroeder JN, Bisel HF, Mrazek R, Hummel RP (1969) Phase II study of hexamethylmelamine (NSC 13875). Cancer 23:132–136PubMedCrossRefGoogle Scholar
  77. 77.
    Yagoda A (1980) Chemotherapy of metastatic bladder cancer. Cancer 45:1879–1888PubMedGoogle Scholar
  78. 78.
    Yagoda A (1979) Phase II trials with cisdiamminedichloride II in the treatment of urothelial cancers. Cancer Treat Rep 63:1565–1572PubMedGoogle Scholar
  79. 79.
    Yagoda A, Watson RC, Grabstald H, Barzell WE, Whitmore WF (1977) Adriamycin and cyclophosphamide in advanced bladder cancer. Cancer Treat Rep 61:97–99PubMedGoogle Scholar
  80. 80.
    Yagoda A, Watson RC, Whitmore WF, Grabstadt H, Middleman MP, Krakoff IH (1977) Adriamycin in advanced urinary tract cancer. Experience in 42 patients and review of the literature. Cancer 39:279–285PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • W. G. Harker
    • 1
  • F. M. Torti
    • 1
  1. 1.Division of Medical Oncology, Department of MedicineStanford University Medical CenterStanfordUSA

Personalised recommendations